Apolipoprotein E moderates the association between Non- APOE Polygenic Risk Score for Alzheimer's Disease and Aging on Preclinical Cognitive Function

medRxiv [Preprint]. 2023 Jun 12:2023.06.09.23291215. doi: 10.1101/2023.06.09.23291215.

Abstract

Introduction: Variation in preclinical cognitive decline suggests additional genetic factors related to Alzheimer's disease (e.g., a non-APOE polygenic risk scores [PRS]) may interact with the APOE ε4 allele to influence cognitive decline.

Methods: We tested the PRS×APOE ε4×age interaction on preclinical cognition using longitudinal data from the Wisconsin Registry for Alzheimer's Prevention. All analyses were fitted using a linear mixed-effects model and adjusted for within individual/family correlation among 1,190 individuals.

Results: We found statistically significant PRS×APOE ε4×age interactions on immediate learning (P=0.038), delayed recall (P<0.001), and Preclinical Alzheimer's Cognitive Composite 3 score (P=0.026). PRS-related differences in overall and memory-related cognitive domains between people with and without APOE ε4 emerge around age 70, with a much stronger adverse PRS effect among APOE ε4 carriers. The findings were replicated in a population-based cohort.

Discussion: APOE ε4 can modify the association between PRS and cognition decline.

Keywords: APOE; PRS; aging; cognition; interaction.

Publication types

  • Preprint